Association of glucocorticoid doses and emotional health in lupus low disease activity state (LLDAS): a cross-sectional study

Table 2 Primary analysis: association between the glucocorticoid dose and emotional health (complete case analysis)

	Crude		Adjusted
Variables	β coefficient [95%CI]	P value	β coefficient [95%CI]	P value
Glucocorticoid, mg/day (per additional mg/day)	− 2.12 [− 3.99, − 0.26]	0.03	− 2.54 [− 4.48, − 0.60]	0.01
Age, years (per 1 year older)			− 0.20 [− 0.55, 0.16]	0.28
Sex, female (vs. male)			11.81 [− 2.10, 25.72]	0.10
Damage index (SDI), point (per additional point)			− 0.90 [− 4.36, 2.55]	0.61
Time since diagnosis of SLE, year (per additional year)			0.30 [− 0.15, 0.75]	0.19
Disease activity index (SLEDAI-2 K), point (per additional point)			− 0.77 [− 3.37, 1.83]	0.56
Hydroxychloroquine (vs. absent)			0.56 [−8.96, 10.07]	0.91
Antipsychotics (vs. absent)			− 1.29 [− 18.88, 16.30]	0.89
Number of immunosuppressants (per additional count)			5.00 [− 1.42, 11.42]	0.13

Note: Covariates: Crude: unadjusted. Adjusted: adjusted for age at the time of the survey, sex, time since diagnosis of SLE, damage index, disease activity index, current use of psychotropics (hypnotics, mood stabilizers, anxiolytics, antidepressants, antipsychotics) and the presence of the immunomodulator hydroxychloroquine
SDI Systemic Lupus International Collaborating Clinics (SLICC)/American College of Rheumatology (ACR) Damage Index, SLEDAI-2 K Systemic Lupus Erythematosus Disease Activity Index 2000, SLE systemic lupus erythematosus. 95% confidence intervals (CI) in brackets

ISSN: 1478-6362